



## EXHIBIT A

Effect of a fat spread enriched with medium-chain triacylglycerols and a special fatty acid-micronutrient combination on cardio-metabolic risk factors in overweight patients with diabetes <sup>1,2,3</sup>

Roswitha Siener<sup>4</sup>, Christina Ehrhardt<sup>5</sup>, Norman Bitterlich<sup>6</sup>, Christine Metzner <sup>4,7\*</sup>

<sup>4</sup> Medical Nutrition Science, Department of Urology, University of Bonn, Bonn, Germany

<sup>5</sup> Bonn Education Association for Dietetics r. A., Aachen, Germany

<sup>6</sup> Medicine and Service Ltd, Department of Biostatistics, Chemnitz, Germany

<sup>7</sup> Department of Internal Medicine III, University Hospital, RWTH, Aachen, Germany

*\*Corresponding author:*

Professor Dr. Dr. Christine Metzner

Department of Internal Medicine III

University Hospital RWTH

Pauwels-Straße 30

D-52074 Aachen

Germany

Tel.: +49 241 8080861

Fax: +49 241 8082455

Email: christine.metzner@rwth-aachen.de

<sup>1</sup> Supported by a research grant from basis GmbH, Woerthsee, Germany

<sup>2</sup> None of the authors has a conflict of interest for this manuscript others than that the study has been funded by basis GmbH, Woerthsee, Germany. Prof. Metzner was a consultant for basis GmbH, Woerthsee, Germany.

<sup>3</sup> Supplemental figure 1 is available as online supporting material with the online posting of this paper at <http://jn.nutrition.org>

Author list for indexing: Siener, Ehrhardt, Bitterlich, Metzner

Word count: 3874, number of tables: 4

Supplementary material: online supporting material: 1

Running title: Effect of MCT fat spread in overweight diabetics

34 <sup>8</sup> **Abbreviations used:**

35 AGE, advanced glycation end products; ALAT, alanine-aminotransferase; ANCOVA,  
36 analysis of covariance; ApoB, apolipoprotein B; ASAT, aspartate-aminotransferase;  
37 BMI, body mass index; CRP, C-reactive protein; DHA, docosahexaenoic acid; EPA,  
38 eicosapentaenoic acid, GFR, glomerular filtration rate; GGT, gamma glutamyl  
39 transferase; MDRD, Modification of Diet in Renal Disease; MCT, medium-chain  
40 triacylglycerols; MUFA, monounsaturated fatty acids; n-3-PUFA, omega-3  
41 polyunsaturated fatty acids; TC, total cholesterol; TG, triglycerides; WC, waist  
42 circumference; WHtR, waist-to-height ratio

43

44 **Acknowledgements**

45 We would like to acknowledge Dr Myslik and his team for their efforts on the conduct of  
46 the study.

47

48 **Statement of author's contribution to manuscript**

49 C. M. designed research. R. S. was involved in project conception and overall research  
50 plan.

51 C. E. analyzed dietary intake and conducted monitoring.

52 N. B. performed statistical analysis.

53 R. S., C. E. and C. M. wrote paper.

54 R. S. and C. M. have primary responsibility for final content. All authors read and  
55 approved the final manuscript.

## 56 Abstract

57

58 Medium-chain triacylglycerols (MCT) and omega-3 polyunsaturated fatty acids (n-3-  
59 PUFA) are suggested to be useful for weight management and cardio-metabolic risk  
60 reduction. As abdominal obesity is prevalent in patients with type 2 diabetes, the aim of  
61 this controlled, double-blind study was to investigate the effect of a fat spread enriched  
62 with MCT and a special fatty acid-micronutrient combination on cardio-metabolic risk  
63 factors in overweight diabetic patients. 54 patients were randomized to receive either a  
64 fat spread with 6 g/d MCT (MCT30%) or 1.2 g/d (MCT6%); 43 completed the study.  
65 Analysis was performed according to the median of MCT intake (supplemented and  
66 food-derived MCT). Clinical, anthropometric, blood, 24h-urine parameters and dietary  
67 intake were assessed at baseline and after 12 weeks, respectively. Total MCT intake  
68 >7g/d (MCT>7 group) significantly reduced waist circumference (WC) by  $1.81 \pm 2.69$  cm,  
69 whereas  $\leq 7$  g/d MCT (MCT $\leq 7$  group) increased WC by  $0.32 \pm 3.03$  cm ( $p=0.027$ ), which  
70 is supported by a change in waist-to-height ratio (WHtR) ( $p=0.018$ ). Fasting serum  
71 triglycerides (TG) increased in both groups over time due to dietary habits. On the  
72 contrary, diabetic metabolic situation and urinary albumin excretion did not change  
73 during the intervention. Urinary pH differed significantly between both groups after 12  
74 weeks. Intake of > 7 g/d MCT reduced WC in overweight diabetic patients. Other cardio-  
75 metabolic risk factors were not affected by intervention due to negative changes in  
76 macronutrient intake. Therefore, the suitability of a fat for nutrient enrichment remains to  
77 be challenged. Further studies in alternative low-fat matrices are desirable.

## 78 Introduction

79

80 Evidence indicates the importance of abdominal adipose tissue as endocrine tissue to  
81 be a key for cardio-metabolic risk factors (1). Among patients with type 2 diabetes the  
82 combination of abdominal enlargement and hypertriglyceridemia, so called  
83 "hypertriglyceridemic waist" (HW)<sup>8</sup>, is highly prevalent (2) and has been associated with  
84 a greater degree of subclinical atherosclerosis that may be related to the proatherogenic  
85 lipoprotein changes (3, 4). This lipoprotein changes called atherogenic dyslipidemia are  
86 typically characterized by reduced levels of high-density lipoprotein cholesterol (HDL C),  
87 elevated TG, and an increase in small, dense low-density lipoprotein (LDL) particles (5).  
88 HW has also been proposed to be an important factor increasing C-reactive protein  
89 (CRP) levels and relative coronary risk in patients with type 2 diabetes of any age and  
90 sex (6, 7). Moreover, reactive oxygen species are produced in various tissues under  
91 diabetic conditions leading to an antioxidant depletion and increased lipid oxidation,  
92 advanced glycation end products (AGE), cell damage and endothelial dysfunction (8, 9).

93

94 A supplementation of MCT for conventional dietary fats has been proposed as beneficial  
95 for weight management, since MCT are rapidly absorbed and preferentially transported  
96 through the portal venous system to the liver. The subsequent stimulation of hepatocytic  
97  $\beta$ -oxidation may reduce the circulating fatty acids available to the adipocytes (10).  
98 Moreover, MCT enhances energy expenditure following thermogenesis (11, 12, 13).

99

100 The cardio-metabolic protective effects of omega-3 polyunsaturated fatty acids (n-3-  
101 PUFA) appear to be due to a synergism between multiple mechanisms that involve

antiinflammatory, inflammation-resolving, regulation of transcription factors and gene expression, membrane fluidity and antiarrhythmic and antithrombotic effects (14). Moreover, n-3-PUFA, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been demonstrated to exert beneficial effects in lowering TG levels (15), including in patients with atherogenic dyslipidemia associated diabetes (16, 17).

As fat spread is an important source of fat in the diet, the choice of a spread providing a high-quality fat and micronutrient profile may be an important dietary measure for patients with diabetes. Fat spreads characterized by a combination of MCT, n-3-PUFA and micronutrients have not been evaluated so far in this cohort. Therefore, aim of this study was to assess the benefit of a fat spread characterized by the above mentioned combination on cardio-metabolic risk factors in overweight diabetic patients.

## **Methods**

### *Participants*

Overweight diabetic patients were recruited from the region of Altomuenster, Bavaria, Germany. Both men and women aged 30 to 82 years with a body mass index (BMI) of  $27 \text{ kg/m}^2$  or greater and a WC  $\geq 94 \text{ cm}$  for women and  $\geq 102 \text{ cm}$  for men were included into the study. Overweight diabetic patients were defined by clinical criteria. Individuals taking any medication or nutritional supplements for weight reduction were excluded. Further exclusion criteria comprised the supplementation and/or therapy with marine n-3-PUFA, micronutrients, treatment with glitazones and/or telmisartan, insulin-dependent

diabetes, ketoacidosis and acute or chronic diarrhoea. Characteristics of patients are shown in Table 2. The study was approved by the Ethics Committee of the Bavarian Chamber of Physicians, Munich, Germany, and all patients provided informed consent before study onset.

### *Study design*

This prospective study was carried out in a double-blind controlled manner. Patients were randomly assigned to receive fat spread with either 6 g/d (MCT30%) or 1.2 g/d MCT (MCT6%), which were equally enriched with special unsaturated fatty acids and micronutrients (Table 1). Patients were asked to consume 2 x 15 g/d of the fat spreads (MCT30% or MCT6%, respectively) for 12 weeks as substitution for their usual dietary spread and to maintain their common diet and physical activity level during the study.

Data were analyzed at baseline and 12 weeks of intervention. Body weight (kg), height (cm) and WC (cm) were measured to the nearest 0.1. Measurement of WC was documented by photography. Anthropometric measurements and venous blood samples were performed in the morning after an overnight fasting period of at least 12 h. Dietary intake data (3-day food record) was analyzed using PRODI 5.5 software (WVG, Stuttgart, Germany). The average of three days was assessed. Glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) study equation (18). Compliance was monitored by weighing of returned spread tubs at week 8 and 12 of intervention as well as by evaluating dietary records on which the number of spread servings per day were recorded. Analysis was performed according to the median of MCT intake (supplemented and food-derived MCT), which was 7 g/d MCT.

150

151 *Laboratory methods*

152 SYSCOMP GmbH, Augsburg, Germany, conducted all laboratory analyses. Analysis of  
153 serum and 24h-urine parameters were performed by standard methods with the  
154 exception of: HbA1c, turbidimetric immunologic inhibition assay (TINIA); Insulin, ECLIA;  
155 Cholesterol, CHOD-PAP method; LDL C and HDL C; enzymatic colour test;  
156 triglycerides, GPO PAP method CRP sensitive, turbidimetry from 22th of September  
157 2009 on.

158

159 *Statistical methods*

160 All data are presented as means  $\pm$  standard deviation. Significance was set at p-value  
161 0.05 (two-sided). Changes of WC and body weight from baseline were determined using  
162 non-parametric analyses (exact Mann-Whitney-U-test). Pre-post intervention changes of  
163 all other variables were analyzed via non-parametric Wilcoxon test and inter group  
164 differences were compared using Mann-Whitney-U test. ANCOVA including use of WC  
165 change as a covariate was used to control for the potential confounder of serum fasting  
166 TG. Data analysis was performed based on the per protocol population and by using  
167 SPSS® for Windows (version PASW 18.0).

168

169

## 170 Results

171

### 172 *Participants*

173 A total of 54 overweight diabetic patients were recruited, of whom 43 were included into  
174 the per protocol (PP) population (24 men and 19 women). Reasons for an exclusion  
175 from the PP population included poor compliance as determined by more than 20%  
176 variance of product consumption (n = 7) and variation in study duration of more than 7  
177 days (n = 2). Moreover, 2 patients left the study due to personal reasons. Both fat  
178 spreads were well tolerated by the patients and the majority of patients followed the  
179 treatment without any reported difficulty.

180

181 At baseline, both groups did not differ regarding anthropometric, clinical and biochemical  
182 parameters (Table 2). Metformin was used as anti-diabetic medication by 20 and  
183 sulfonylurea by 13 patients. Statins were taken as cholesterol-lowering medication by 11  
184 and antihypertensive medication (beta-blocker, angiotensin converting enzyme inhibitors  
185 and calcium channel blocker) by 49 patients.

186

### 187 *Clinical measurements*

188 A total MCT intake > 7 g/d (n = 21) significantly reduced WC by  $1.81 \pm 2.69$  cm (p =  
189 0.005), whereas no significant change was observed in the MCT≤7 group (n = 22) ( $0.32$   
190  $\pm 3.03$  cm, p = 1.000) over time (Table 2). The inter-group changes differed significantly  
191 (p = 0.027). Additionally, a significant difference in waist-to-height ratio (WHtR) was  
192 observed between groups (p = 0.018), whereas BMI and body weight changes did not

change significantly. Systolic and diastolic blood pressure remained unaffected by the supplementation in both groups.

#### *Serum parameters*

The average value of fasting TG was below the cut-off level of 150 mg/dL in the MCT>7 group ( $147.3 \pm 92.0$  mg/dL), whereas the fasting triglyceride level of the MCT≤7 group was hypertriglyceridemic ( $166.5 \pm 113.3$  mg/dL) (Table 2). Over time, fasting TG increased significantly in both groups ( $p = 0.021$  and  $p = 0.022$ , respectively), but there was no inter-group difference. Total cholesterol, LDL-C, HDL-C, and TC/HDL-C ratio did not change during supplementation. Fasting glucose, insulin, HOMA index, glycated hemoglobin (HbA1c) and CRP were elevated in both groups during the study, but were not affected by intervention. The same applies to aspartate-aminotransferase (ASAT) and alanine-aminotransferase (ALAT), however gamma-glutamyltransferase (GGT) increased significantly in the MCT≤7 group ( $p = 0.023$ ). In the MCT≤7 group, uric acid increased significantly during supplementation ( $p = 0.024$ ), but remained within the normal range.

#### *Urine parameters*

Whereas no changes were observed for GFR, urinary albumin and sodium excretion, urinary pH varied significantly between groups after 12 weeks of intervention ( $p = 0.032$ ) (Table 2).

### *Dietary intake*

Except for the MCT intake, there was no significant difference in nutrient consumption between the both groups (Table 3). However, the relation of macronutrients shifted due to changes in dietary habits. Fat intake and percentage of energy consumed from fat increased during supplementation, however this change was not significant in the MCT>7 group. Saturated fat intake was found to be significantly elevated in the MCT>7 group by  $7.3 \pm 11.7$  g/d ( $p = 0.016$ ), mainly due to supplementation. PUFA consumption increased significantly only in the MCT>7 group ( $p = 0.033$ ), whereas MUFA intake, including oleic acid, was significantly higher following the fat spread consumption in both groups ( $p < 0.039$  and  $0.010$ , respectively). The same applied for daily oleic acid, ALA, EPA and DHA intake. Glucose, fructose, sorbitol and purine intake remained stable over time. However, the fat spread consumption affected daily vitamin supply, as revealed by a significant increase in vitamin D, B2 and folic acid intake after 12 weeks in both groups. Vitamin E intake rose in the MCT>7 group, and nicotinic acid as well as vitamin B6 consumption were significantly enhanced over time in the MCT≤7 group.

### **Discussion**

To our knowledge this is the first study investigating the effect of a fat spread enriched with MCT and a special fatty acid-micronutrient combination on cardio-metabolic risk factors in overweight diabetic patients. The major finding of the present study was a significant decrease in WC in the MCT>7 group. The reduction in WC observed in this study is in accordance with previous research evaluating the effect of MCT in overweight

subjects (19, 20, 21). The supplementation of 5 g/d MCT in form of an oil for instance resulted in a significant WC decrease compared to the LCT control treatment ( $-5.1 \pm 3.1$  cm vs.  $-3.3 \pm 1.9$  cm,  $p < 0.05$ ) (19). Tsuji et al. (21) reported a significant reduction in WC by  $5.67 \pm 0.05$  cm with  $\text{BMI} \geq 23 \text{ kg/m}^2$ , however only in the area of subcutaneous fat, at a total daily MCT intake of 9.24 g/d.

Since some evidence also pointed at a beneficial effect on satiety (22), it has been proposed that under free living conditions an increase in dietary MCT may result in less energy intake and contributes to weight management. However, the fact that we did not observed any decrease in energy intake and no change in body weight suggests that the observed effect on WC may be rather ascribed to an effect on energy expenditure and thermogenesis than to an increase in satiety (13, 23, 24).

Since long-chain PUFA are proposed to reduce TG, we hypothesized that the intervention may involve an improvement in dyslipidemia. However, in our study the consumption of the fat spreads did not result in any reductions in blood lipids. In contrast, we observed a significant rise in fasting TG in both groups after supplementation. It is suggested that fasting TG may have been affected by changes in dietary habits regarding the quantity and quality of fat intake. Fatty acid intake profile of patients revealed a rise in the intake from MUFA, especially oleic acid, in both groups. Table 4 shows that TG-lowering effect could be attributed only to MCT intake, whereas MUFA increased serum TG.

262 This rise in fat consumption may have counteracted any beneficial effects of the n-3  
263 PUFA and may have caused the adverse effect on fasting TG instead. It further  
264 indicates that the spreadable fat has not fully been consumed as a replacement of other  
265 fat in the diet as intended, but rather in addition. In deed, several patients reported that  
266 the consumption of 30g/d of spread during the study was much higher than the amount  
267 of spread they usually consume which was reflected in their dietary protocols. However,  
268 observations in free-living conditions illustrated that users of plant sterol enriched  
269 margarines generally consumed less than the 20g/d recommended by the  
270 manufacturers. The average daily intake of phytosterol-enriched margarine ranged  
271 between 9 and 14 g (25), indicating that the serving size chosen in this study may not be  
272 consistent with habitual spread intake in Europe. Unpredictable effects such as changes  
273 in physical activity and nutritional behaviour over time which are difficult to control for  
274 may bias results even in carefully designed studies (26).

275

276 An additional effect on fasting TG may have been expected due to n-3 PUFA  
277 supplementation with the fat spreads. With combined daily intake of 240 mg DHA + EPA  
278 and 870/900 mg ALA, the n-3-PUFA intake may have been too low to produce a  
279 significant triglyceride-lowering effect. The recommended daily intake of n-3-PUFA for  
280 the treatment of hypertriglyceridemia is 2 to 4 g (15).

281

282 The consumption of the fat spreads did not have any adverse affects on fasting glucose,  
283 insulin, HOMA index, HbA1c, ASAT or ALAT. As GGT increased in MCT $\leq$ 7 group, no  
284 general effect of MCT supplementation on GGT could be derived.

285

286 The observed reduction in urinary pH in the MCT>7 group may be referred to the fact  
287 that MCT have a ketogenic character, as acetyl-CoA produced during medium-chain  
288 fatty acid oxidation is directed towards ketone body production (10). Additionally, oral  
289 administration of MCT leads to urinary elimination of C6, C8 and C10 dicarboxylic acid  
290 (27, 28).

291

292 Since the fat spreads were also enriched with fat soluble vitamins A, D3 and E, their  
293 consumption added to a significant increase in the daily supply of these essential  
294 nutrients and thus, ameliorated antioxidant and vitamin D3 status. These changes may  
295 exert favourable effects on cardio-metabolic risk factors (29, 30).

296

297 In summary, a daily intake of at least 7 g MCT beneficially affects visceral fat mass,  
298 objectivised as WC, in overweight diabetic patients. As the daily intake of MCT through  
299 the normal diet is relatively small, a moderate enrichment of food with MCT may  
300 effectively contribute to achieve this required intake. The supply of MCT through  
301 enriched fat spreads may be adequate for individuals who are used to consume a high  
302 amount of spread on a daily basis. But, it may be reasonable to reassess the suitability  
303 of a fat spread as matrix for MCT. As dietary counselling for diabetic patients includes  
304 recommendations to reduce and modify the fat intake, alternative food matrices such as  
305 oil and milk products may be interesting alternatives in order to ensure an healthy  
306 overall diet.

307

308

## References

1. Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. *Biochem Soc Trans.* 2005;33:1078-81.
2. Kahn HS, Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. *Am J Clin Nutr.* 2003;78:928-34.
3. Sam S, Haffner S, Davidson MH, D'Agostino RB, Feinstein S, Kondos G, Perez A, Mazzone T. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. *Diabetes Care.* 2009;32:1916-20.
4. Blackburn P, Lemieux I, Alméras N, Bergeron J, Cote M, Tremblay A, Lamarche B, Despres JP. The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile. *Metabolism.* 2009;58:1123-30.
5. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *Circulation.* 2002;106:3143-421.
6. Rogowski O, Shapira I, Steinvil A, Berliner S. Low-grade inflammation in individuals with the hypertriglyceridemic waist phenotype: another feature of the atherogenic dysmetabolism. *Metabolism.* 2009;58:661-7.
7. Rosolova H, Petrlova B, Simon J, Sifalda P, Sipova I. High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome. *Med Sci Monit.* 2008;14:CR411-5.

8. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. *Diabetes*. 1999;48:1-9.
9. Whiting PH, Kalansooriya A, Holbrook I, Haddad F, Jennings PE. The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. *Br J Biomed Sci* 2008;65:71-4.
10. Bach AC, Ingenbleek Y, Frey A. The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy? *J Lipid Res*. 1996;37:708-26.
11. Beermann C, Jelinek J, Reinecker T, Hauenschild A, Boehm G, Kloer HU. Short term effects of dietary medium-chain fatty acids and n-3 long-chain polyunsaturated fatty acids on the fat metabolism of healthy volunteers. *Lipids Health Dis*. 2003;2:1-10.
12. Johnson RC, Young SK, Cotter R, Lin L, Rowe WB. Medium-chain-triglyceride lipid emulsion: Metabolism and tissue distribution. *Am J Clin Nutr*. 1990;52:502-8.
13. Scalfi L, Coltorti A, Contaldo F. Postprandial thermogenesis in lean and obese subjects after meals supplemented with medium-chain and long-chain triglycerides. *Am J Clin Nutr*. 1991;53:1130-3.
14. Adkins Y, Kelly DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. *J Nutr Biochem*. 2010.
15. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation*. 2002;106:2747-57.
16. Zeman M, Zak A, Vecka M, Tvrzicka E, Pisarikova A, Stankova B. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. *J Nutr Biochem*. 2006;17:379-84.

17. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HAW. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. *Diabetologia*. 2007; 50:1593-602.
18. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem*. 2007;53:766-72.
19. Nosaka N, Maki H, Suzuki Y, Haruna H, Ohara A, Kasai M, Tsuji H, Toshiaki A, Okazaki M, et al. Effects of margarine containing medium-chain triacylglycerols on body fat reduction in humans. *J Atheroscler Thromb*. 2003;10: 290-8.
20. Liu Y, Wang J, Zhang R, Zhang Y, Xu Q, Zhang J, Zhang Y, Zheng Z, Yu X, et al. A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects. *Asia Pac J Clin Nutr*. 2009;18:351-8.
21. Tsuji H, Kasai M, Takeuchi H, Nakamura M, Okazaki M, Kondo K. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women. *J Nutr*. 2001;131:2853-9.
22. Furuse M, Choi YH, Mabayo RT, Okumura JI. Feeding behavior in rats fed diets containing medium chain triglyceride. *Physiol Behav*. 1992;52:815-7.
23. St-Onge MP, Ross R, Parsons WD, Jones PJH. Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men. *Obes Res*. 2003;11:395-402.

24. Dulloo AG, Fathi M, Mensi N, Giardier L. Twenty-four-hour energy expenditure and urinary catecholamines of humans consuming low-to-moderate amounts of medium-chain triglycerides: a dose-response study in a human respiratory chamber. *Eur J Clin Nutr.* 1996;50:152-8.
25. Fransen HP, de Jong N, Wolfs M, Verhagen H, Verschuren WMM, Lütjohann D, von Bergmann K, Plat J, Mensink RP. Customary use of plant sterol and plant stanol enriched margarine is associated with changes in serum plant sterols and stanol concentrations in humans. *J Nutr.* 2007;137:1301-6.
26. Zunft HJF, Lüder W, Harde A, Haber B, Graubaum HJ, Koebnick C, Grünwald J. Carob pulp preparation rich in insoluble fiber lowers total and LDL cholesterol in hypercholesterolemic patients. *Eur J Nutr.* 2003;42:235-42.
27. Mortensen PB. The possible antiketogenic and gluconeogenic effects of the beta-oxidation of fatty acids in rats. *Biochim Biophys Acta.* 1980; 620:177-85.
28. Lima LAM, Gray OP, Losty H. Excretion of dicarboxylic acids following administration of medium chain triglycerides. *J Parenter Enterol Nutr.* 1987;11:600-1.
29. Zittermann A, Frisch S, Berthold HK, Goetting C, Kuhn J, Kleesiek K, Stehle P, Koertke H, Koerfer R. Vitamin D supplementation enhances beneficial effects of weight loss on cardiovascular risk markers. *Am J Clin Nutr.* 2009;89:1321-7.
30. Shargorodsky M, Debby O, Matas Z, Zimlichman R. Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors, and inflammatory markers in patients with multiple cardiovascular risk factors. *Nutr Metab.* 2010; 7:55.

Table 1: Mean composition of the MCT30% and MCT6% fat spread per daily serving (2 x 15g)<sup>1</sup>

	MCT30%	MCT6%
Energy (kcal)	176	176
Carbohydrates (g)	0	0
Protein (g)	0	0
Fat (g)	19.5	19.5
Fatty acids		
SAFA (g)	8.7	7.2
- MCT (g)	6.0	1.2
- SAFA without MCT (g)	2.7	6.0
MUFA (g)	6.9	8.1
- Oleic acid (g)	6.6	7.8
PUFA (g)	3.9	4.2
- LA (g)	2.88	3.1
- ALA (g)	0.87	0.9
- EPA (g)	0.15	0.15
- DHA (g)	0.09	0.09
Trans fatty acids (g)	0.12	0.09
Cholesterol (g)	0.006	0.006
Micronutrients		
Vitamin A (µg RE)	240	240
Vitamin B1(mg)	0.45	0.45
Vitamin B2 (mg)	0.48	0.48
Nicotinic acid (mg)	4.95	4.95
Vitamin B6 (mg)	0.48	0.48
Folic acid (µg)	120	120
Vitamin B12 (µg)	1.95	1.95
Vitamin D3 (µg)	1.8	1.8
Vitamin E (mg)	3.3	3.3
Sodium (g)	0.002	0.002
Chrome (mg)	0.015	0.015
Manganese (mg)	0.6	0.6

<sup>1</sup> abbreviations used: ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linolenic acid; MCT, medium-chain triacylglycerols; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids ; RE, retinol equivalent; SAFA, saturated fatty acids

Table 2: Clinical and biochemical characteristics at baseline and after supplementation<sup>1</sup>

	MCT intake > 7 g/d (n = 21)				MCT intake ≤ 7 g/d (n = 22)				P <sup>a</sup>	P <sup>b</sup>
	wk 0	wk 12	wk 12 - 0	P <sup>a</sup>	wk 0	wk 12	wk 12 - 0	P <sup>a</sup>		
Weight (kg)	95.7 ± 21.2	95.3 ± 21.7	-0.35 ± 1.92	0.641	87.7 ± 11.6	88.3 ± 11.7	0.54 ± 1.76	0.118	0.177	
BMI (kg/m <sup>2</sup> )	34.35 ± 6.84	34.23 ± 7.08	-0.12 ± 0.70	0.681	31.69 ± 4.05	31.89 ± 4.10	0.20 ± 0.61	0.092	0.174	
WC (cm)	112.5 ± 12.5	110.7 ± 12.9	-1.81 ± 2.69	0.005	106.4 ± 6.6	106.7 ± 7.0	0.32 ± 3.03	1.000	0.027	
WHR	0.676 ± 0.076	0.665 ± 0.079	-0.010 ± 0.016	0.008	0.640 ± 0.045	0.642 ± 0.049	0.002 ± 0.018	0.920	0.018	
SBP (mmHg)	138.6 ± 18.4	137.9 ± 12.0	-0.7 ± 13.2	0.792	148.4 ± 18.6	142.0 ± 17.2	-6.4 ± 15.4	0.069	0.249	
DBP (mmHg)	84.8 ± 11.7	84.1 ± 7.7	-0.7 ± 10.3	0.707	87.7 ± 8.7	85.2 ± 8.7	-2.5 ± 9.2	0.170	0.612	
Fasting TG (mg/dl)	147.3 ± 92.0	181.6 ± 122.7	34.2 ± 72.6	0.021	166.5 ± 113.3	216.6 ± 177.1	50.1 ± 108.1	0.022	0.990	
TC (mg/dl)	209.5 ± 41.0	214.0 ± 41.6	4.52 ± 18.60	0.177	217.7 ± 37.9	225.4 ± 42.7	7.68 ± 23.04	0.058	0.527	
LDL-C (mg/dl)	128.8 ± 34.9	130.7 ± 32.3	1.95 ± 16.59	0.357	136.4 ± 34.9	135.6 ± 40.1	-0.86 ± 22.04	0.848	0.618	
HDL-C (mg/dl)	52.1 ± 10.8	49.7 ± 10.6	-2.39 ± 8.75	0.230	49.5 ± 9.9	51.4 ± 13.9	1.88 ± 6.71	0.363	0.085	
TC/ HDL-C	4.15 ± 0.98	4.50 ± 1.37	0.35 ± 0.82	0.064	4.51 ± 1.01	4.65 ± 1.50	0.14 ± 0.70	0.637	0.289	
Fasting glucose (mg/dl)	127.5 ± 21.8	132.0 ± 29.7	4.48 ± 19.91	0.422	124.4 ± 23.9	126.5 ± 34.6	2.09 ± 18.70	0.676	0.313	
Fasting insulin (μU/ml)	12.6 ± 9.1	13.7 ± 11.0	1.09 ± 9.33	0.509	14.4 ± 6.8	17.6 ± 25.4	3.17 ± 24.16	0.299	0.177	
HOMA-Index	4.14 ± 3.73	4.81 ± 5.52	0.68 ± 5.21	0.639	4.46 ± 2.39	5.72 ± 9.01	1.26 ± 8.68	0.306	0.234	
HbA1c (%)	6.76 ± 0.58	6.69 ± 0.78	-0.067 ± 0.380	0.367	6.46 ± 0.47	6.46 ± 0.53	0.004 ± 0.208	0.844	0.179	
CRP (mg/l)	6.17 ± 5.97	5.52 ± 4.91	-0.66 ± 2.77	0.140	5.80 ± 8.46	4.45 ± 4.63	-1.35 ± 6.76	0.274	0.961	
Uric acid (mg/l)	5.96 ± 1.53	6.27 ± 1.52	0.31 ± 0.66	0.024	6.58 ± 1.04	6.58 ± 1.04	0.00 ± 1.09	0.944	0.103	
GGT (U/l)	43.8 ± 50.1	41.2 ± 26.4	-2.57 ± 27.84	0.265	43.8 ± 47.6	44.2 ± 30.5	0.45 ± 20.82	0.023	0.442	
ASAT (U/l)	28.4 ± 10.6	28.0 ± 8.3	-0.43 ± 5.97	0.861	28.1 ± 11.9	27.1 ± 6.5	-1.00 ± 9.01	0.480	0.643	
ALAT (U/l)	33.5 ± 21.8	31.2 ± 14.3	-2.24 ± 9.96	0.650	29.2 ± 14.1	30.4 ± 13.8	1.18 ± 10.77	0.166	0.607	
GFR (mL/min/1.73 m <sup>2</sup> )	87.9 ± 19.1	86.4 ± 22.4	-1.54 ± 11.28	0.433	81.7 ± 15.7	83.4 ± 14.9	1.71 ± 8.60	0.095	0.290	
U-Albumin (mg/24h)	55.3 ± 199.4	19.5 ± 39.9	-35.8 ± 162.7	0.594	62.1 ± 225.8	60.0 ± 150.1	-2.1 ± 109.3	0.641	0.842	
U-pH (24h)	5.81 ± 0.81	5.52 ± 0.73	-0.29 ± 0.70	0.062	5.80 ± 1.08	6.05 ± 1.12	0.25 ± 0.88	0.176	0.032	
U-Sodium (mmol/24h)	212.0 ± 84.6	234.5 ± 89.0	22.5 ± 78.2	0.145	208.6 ± 67.6	231.0 ± 75.6	22.4 ± 72.2	0.153	1.000	

<sup>1</sup> data are presented as mean ± SD

<sup>a</sup> p values for comparison between week 0 and 12 (Wilcoxon-Test),

<sup>b</sup> p value calculation for comparison between week 0 and 12 based on Mann-Whitney-U-Test

<sup>2</sup> abbreviations used: ASAT, aspartate-aminotransferase; ALAT, alanine-aminotransferase; CRP, C reactive protein; DBP, diastolic blood pressure; GFR, glomerular filtration rate; GGT, gamma-glutamyltransferase; HbA1c, glycated haemoglobin; MCT, medium chain triglycerols SBP, systolic blood pressure; TC, total cholesterol; WC, waist circumference; WHtR, waist to height ratio; U-albumin, urine albumin; U-pH, urine pH; U-sodium, urine sodium

Table 3: Daily dietary intake at baseline and after supplementation<sup>1,2</sup>

	MCT intake > 7g/d (n = 21)				MTC intake ≤ 7g/d (n = 22)				P <sup>b</sup>
	wk 0	wk 12	wk 12 – 0	P <sup>a</sup>	wk 0	wk 12	wk 12 – 0	P <sup>a</sup>	
Energy (kcal/d)	2341.9 ± 650.0	2440.4 ± 758.4	98.5 ± 601.3	0.566	2234.4 ± 950.3	2518.8 ± 1095.4	284.5 ± 1229.6	0.223	0.593
Protein (g/d)	95.6 ± 22.7	93.4 ± 40.7	-2.2 ± 37.9	0.498	90.6 ± 45.7	102.7 ± 57.6	12.1 ± 67.3	0.263	0.211
Protein (%EN)	16.89 ± 2.23	15.43 ± 2.90	-1.47 ± 2.92	0.027	16.27 ± 3.10	16.13 ± 2.72	-0.14 ± 3.55	0.592	0.198
Carbohydrates (g/d)	237.0 ± 59.3	237.2 ± 62.3	0.2 ± 58.1	0.931	240.9 ± 96.9	241.1 ± 86.0	0.2 ± 109.3	0.808	0.771
Carbohydrates (%EN)	41.42 ± 6.35	40.53 ± 7.14	-0.89 ± 5.83	0.715	44.79 ± 7.74	40.27 ± 7.65	-4.51 ± 7.53	0.014	0.076
Fat (g/d)	93.4 ± 30.4	106.6 ± 37.6	13.2 ± 30.2	0.068	89.1 ± 47.0	111.0 ± 57.6	21.9 ± 60.5	0.050	0.789
Fat (%EN)	36.4 ± 5.5	39.4 ± 4.7	3.03 ± 6.16	0.079	35.1 ± 6.2	39.1 ± 5.8	4.04 ± 6.04	0.006	0.423
Alcohol (g/d)	21.3 ± 35.4	19.3 ± 28.2	-1.96 ± 16.86	0.476	11.8 ± 20.2	17.9 ± 27.6	6.03 ± 24.84	0.227	0.206
Alcohol (%EN)	5.33 ± 7.61	4.66 ± 6.29	-0.67 ± 3.29	0.590	3.86 ± 6.05	4.48 ± 6.58	0.62 ± 5.65	0.872	0.771
Cholesterol (mg/d)	363.2 ± 145.2	393.6 ± 213.7	30.4 ± 160.4	0.543	332.4 ± 189.0	359.7 ± 193.7	27.2 ± 259.2	0.758	0.884
SAFA (g/d)	34.6 ± 13.9	41.9 ± 13.5	7.3 ± 11.7	0.016	32.4 ± 17.7	40.2 ± 18.8	7.8 ± 21.1	0.072	0.942
MCT (g/d)	1.31 ± 0.76	7.74 ± 0.56	6.43 ± 0.83	< 0.001	1.08 ± 0.64	4.94 ± 2.12	3.86 ± 2.29	< 0.001	< 0.001
MUFA (g/d)	34.0 ± 12.3	39.9 ± 16.0	5.9 ± 13.5	0.039	34.1 ± 19.9	45.5 ± 26.5	11.3 ± 27.1	0.010	0.627
PUFA (g/d)	14.5 ± 6.6	16.8 ± 5.7	2.3 ± 6.6	0.033	14.7 ± 7.7	18.2 ± 9.0	3.4 ± 9.5	0.082	0.981
Oleic acid (g/d)	30.1 ± 11.2	35.8 ± 14.4	5.7 ± 12.5	0.039	30.1 ± 17.7	40.7 ± 24.5	10.7 ± 24.6	0.011	0.610
LA (g/d)	12.34 ± 5.76	13.79 ± 4.98	1.45 ± 5.61	0.073	12.91 ± 6.88	15.21 ± 8.09	2.30 ± 8.30	0.322	0.981
ALA (g/d)	1.35 ± 0.82	2.09 ± 0.38	0.74 ± 0.78	0.001	1.15 ± 0.54	2.03 ± 0.66	0.88 ± 0.79	< 0.001	0.409
LA/ALA	9.60 ± 1.87	6.47 ± 1.23	-3.14 ± 2.08	< 0.001	11.37 ± 3.70	7.22 ± 1.70	-4.15 ± 3.43	< 0.001	0.395
EPA (g/d)	0.040 ± 0.038	0.187 ± 0.035	0.147 ± 0.048	< 0.001	0.035 ± 0.039	0.178 ± 0.027	0.143 ± 0.049	< 0.001	0.981
DHA (g/d)	0.075 ± 0.085	0.192 ± 0.148	0.117 ± 0.167	0.003	0.068 ± 0.116	0.152 ± 0.071	0.083 ± 0.151	0.001	0.752
LA/(ALA+EPA+DHA)	8.72 ± 1.63	5.50 ± 1.11	-3.22 ± 1.65	< 0.001	10.56 ± 3.67	6.20 ± 1.57	-4.35 ± 3.35	< 0.001	0.296
Glucose (g/d)	11.4 ± 6.4	13.7 ± 6.1	2.3 ± 7.0	0.106	14.7 ± 7.4	13.7 ± 8.9	-1.0 ± 8.8	0.661	0.174
Fructose (g/d)	16.7 ± 10.4	17.7 ± 8.8	1.0 ± 11.6	0.532	20.2 ± 9.3	18.0 ± 11.1	-2.1 ± 12.2	0.527	0.296
Sorbitol (g/d)	1.01 ± 0.83	1.25 ± 1.12	0.24 ± 1.37	0.498	1.01 ± 0.58	1.70 ± 1.46	0.69 ± 1.49	0.051	0.437

Table 3: ... continuation

	MCT intake > 7g/d (n = 21)			MTC intake ≤ 7g/d (n = 22)			P <sup>b</sup>	
	wk 0	wk 12	wk 12 - 0	P <sup>a</sup>	wk 0	wk 12		
Retinol (RE µg/d)	3093.4 ± 6769.2	1671.6 ± 825.4	-1421.8 ± 6808.4	0.434	2611.9 ± 3613.9	1845.3 ± 792.9	-766.5 ± 3442.7	0.783
Vitamin D (µg/d)	3.09 ± 3.68	5.54 ± 4.76	2.45 ± 6.08	0.010	2.48 ± 3.58	3.54 ± 2.01	1.06 ± 4.36	0.042
Vitamin E (mg/d)	11.01 ± 5.25	14.45 ± 4.25	3.44 ± 4.66	0.004	12.10 ± 5.65	15.03 ± 7.19	2.92 ± 7.60	0.077
Vitamin B2 (mg/d)	1.77 ± 0.98	2.18 ± 0.65	0.41 ± 1.03	0.008	1.59 ± 0.72	2.26 ± 1.04	0.67 ± 1.24	0.006
Nicotinic acid (mg/d)	22.5 ± 8.8	25.9 ± 9.3	3.5 ± 12.2	0.217	19.5 ± 8.3	29.3 ± 15.0	9.8 ± 15.0	<0.001
Vitamin B6 (mg/d)	2.11 ± 0.80	2.52 ± 1.31	0.41 ± 1.17	0.122	1.98 ± 0.89	2.75 ± 1.31	0.77 ± 1.44	0.002
Folic acid (µg/d)	250.4 ± 157.3	354.1 ± 88.9	103.7 ± 119.1	0.001	239.5 ± 82.7	371.5 ± 139.4	131.9 ± 153.3	<0.001
Vitamin B12 (µg/d)	11.14 ± 15.76	10.54 ± 4.74	-0.61 ± 16.15	0.063	8.65 ± 7.70	10.83 ± 5.19	2.18 ± 9.35	0.050
Vitamin C (mg/d)	92.8 ± 89.2	79.2 ± 29.6	-13.6 ± 86.0	0.848	88.9 ± 40.6	92.3 ± 48.5	3.4 ± 64.1	0.758
Sodium (g/d)	3.14 ± 1.23	3.02 ± 1.24	-0.12 ± 1.10	0.715	3.39 ± 1.87	3.50 ± 2.21	0.11 ± 2.54	0.485
Chloride (g/d)	4.74 ± 1.71	4.62 ± 1.84	-0.12 ± 1.51	0.741	5.03 ± 2.65	5.29 ± 3.38	0.26 ± 3.86	0.592
Salt (g/d)	7.1 ± 2.7	6.9 ± 2.8	-0.2 ± 2.4	0.715	7.5 ± 4.2	7.8 ± 5.1	0.4 ± 5.9	0.509
Fiber (g/d)	21.9 ± 11.7	22.2 ± 7.2	0.32 ± 8.96	0.434	24.1 ± 10.5	25.3 ± 13.4	1.16 ± 14.47	0.910
Purins (mg/d)	203.9 ± 67.0	201.9 ± 98.8	-2.0 ± 111.8	0.821	200.7 ± 98.6	230.1 ± 129.3	27.0 ± 145.5	0.327
Uric acid (mg/d)	613.4 ± 201.4	605.9 ± 297.7	-7.5 ± 336.1	0.794	586.3 ± 279.8	685.2 ± 352.7	98.9 ± 397.4	0.072

<sup>1</sup> data are presented as mean ± SD<sup>a</sup> p values for comparison between week 0 and 12 (Wilcoxon-Test)<sup>b</sup> p values for comparison of group x time interactions (Mann-Whitney-U-Test)<sup>2</sup> abbreviations used: ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; EN, energy; EPA, eicosapentaenoic acid; LA, linoleic acid; MCT, medium chain triacylglycerols; PUFA, polyunsaturated fatty acids; RE, retinol equivalent; SAFA, saturated fatty acids

Table 4: Serum fasting triglycerides depending on change of fatty acid intake<sup>1</sup>

ANCOVA	Oleic acid (g/d)	MUFA* (g/d)	PUFA (g/d)	MCT (g/d)	SAFA** (g/d)	Age (years)	Gender <sup>2</sup> (1 f/2 m)
PP (n = 43) p = 0.471	B: 0.789	B: 2.046	B: -1.710	B: -17.950	B: 0.324	B: -0.050	B: -72.396
	95% CI (-9.84;11.42)	95% CI (-44.8;48.9)	95% CI (-19.0;15.6)	95% CI (-42.1;6.2)	95% CI (-13.5;14.2)	95% CI (-6.2;6.1)	95% CI (-175.5;30.7)
	p = 0.881	p = 0.930	p = 0.842	p = 0.141	p = 0.962	p = 0.987	p = 0.163

\*without oleic acid

\*\*without MC

<sup>1</sup> abbreviations used: MCT, medium chain triacylglycerols; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SAFA, saturated fatty acids

<sup>2</sup> gender is coded by 1 (women) and 2 (men)

Supplemental Figure 1: Trial profile

